Rationale: Report a case of bilateral multiple retinal hamartomas (RAHs) in a patient with tuberous sclerosis complex (TSC) and introduced a new method (subthreshold micropulse laser photocoagulation) for the treatment of RAHs.
Introduction
Tuberous sclerosis complex (TSC) is a systemic genetic disorder characterized by hamartomas in multiple organs. Recent epidemiologic studies show that the incidence of TSC is 1/ 6000 to 1/10,000 live births. [1, 2] Major clinical features of TSC include facial angiofibromas, hypomelanotic macules, retinal hamartomas (RAHs), subependymal giant cell astrocytoma, cardiac rhabdomyomas, and renal angiomyolipomas. [3] These lesions are mainly caused by mutations of TSC1 and TSC2 genes that encode tumor growth suppressors hamartin (TSC1) and tuberin (TSC2). [4, 5] Approximately 75% to 80% patients with TSC are caused by TSC2 mutations, while TSC1 mutations are less common than TSC1, with the prevalence rate of 10% to 30%. [6] Retinal astrocytic hamartoma (RAH) is the most common ophthalmic manifestations in patients with TSC. Reportedly, RAHs occur in 30% to 50% patients with TSC. [3, 7] According to fundus manifestation, RAHs can be classified into 3 types. [8, 9] Type I lesions usually occur as flat, circular, semitransparent, white-gray pattern, and are confined in the retinal nerve fiber layer; type II lesions are prominent, nodular, mulberry-like masses with multiple calcified spots; type III lesions contain the features of both types I and II. Although most RAHs are stationary and do not cause vision impairment, rare cases may develop macular edema, subretinal exudation, exudative retinal detachment, neovascularization, and vitreous hemorrhage. [10] By far, there is no standard treatment for RAHs in patients with TSC. Conventional photocoagulation, [11, 12] photodynamic therapy, [13] intravitreal anti-vascular endothelial growth factor (anti-VEGF), [14, 15] vitreoretinal surgery, [16] and systemic mTOR inhibitor [17] are alternative treatment options for aggressive Editor: N/A.
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RAHs and associated subretinal exudation and neovascularization. However, these treatments are ineffective in many patients and associated with various complications. Here we report a case of TSC with bilateral multiple RAHs and introduce a novel approach of subthreshold micropulse laser photocoagulation (SMLP) therapy in the treatment of RAHs.
Case presentation
A 20-year-old male patient presented to Beijing Tongren Hospital for decreased vision and metamorphosia in both eyes (OU) for 2 months. As the history, he was diagnosed with TSC at the age of 15 and was on regular oral sirolimus (rapamycin) therapy for 5 years. At the initial ophthalmic examination, the best-corrected visual acuity (BCVA) was 20/32 in his right eye (OD) and 20/40 in his left eye (OS). Intraocular pressure was 13 mm Hg in both eyes. Slit-lamp examination showed that the anterior segment was unremarkable. Dilated fundus examination found multiple grayish yellow and slightly elevated lesions with size ranging from 1/4PD to 4PD in both eyes. According to fundus manifestation, the lesions could be classified into 3 types (Fig. 1A, B) . Most of the lesions OD were flat, grayish, translucent, and without calcification, while a lesion in the superiortemporal quadrant had a mulberry-like appearance and demonstrated obvious calcification. Otherwise, the lesions OS consist of multiple calcified spots surrounded by white-gray translucent rings. Ocular B-scan ultrasonography showed a hyperechoic solid mass with calcific foci inferior to the optic nerve in the left eye (Fig. 1C, D) . Fundus autofluorescence (FAF) demonstrated patches of hyperautofluorescence corresponding to the lesions on fundus photography (Fig. 1E, F ). On optical coherence tomography (OCT), the lesion along the inferotemporal vascular arcade in the right eye showed a hyperreflective dome-shaped mass confined to the retinal nerve fiber layer ( Fig. 2A, B ). In the left eye, the lesion inferior to the macula demonstrated uneven elevated retinal nerve fiber layer and a large hyporeflective cavity with high reflectivity dots ( Detailed past medical histories and physical examinations were obtained. The patient developed complex partial seizure at 15 and was diagnosed with TSC based on typical multisystem involvement. Dermatologic examination showed multiple facial angiofibromas on his nose and cheeks in a butterfly distribution (Fig. 3A) . Abdominal computed tomography (CT) scan revealed bilateral multifocal renal hamartomas (Fig. 3B ). Cranial CT and magnetic resonance imaging (MRI) showed typical lesions including intracranial subependymal calcified nodules (Fig. 3C,  D) . Psychologic assessment revealed that the patient had autism and mild intellectual disability, which were spectrums of TSCassociated neuropsychiatric disorders. Oral sirolimus (rapamycin) was administered at an initial daily dose of 2 mg immediately after the diagnosis of TSC. The serum drug concentration, blood cell counts, kidney, and liver functions were monitored. Because of the serum drug concentration was between 15 and 25 ng/mL, the dose was reduced to 1 mg daily and the sirolimus was titrated to serum through concentration of 5 to 10 ng/mL. Despite adequate dosage and duration of sirolimus treatment, one of the renal hamartomas still enlarged rapidly and subsequently oppressed the upper pole and calyx of the right kidney. Thus, the patient underwent partial nephrectomy at 16. Postoperative pathologic examination suggested kidney angiomyolipoma. According to the 2012 International Tuberous Sclerosis Complex Diagnositc Criteria, [3] clinical features of TSC are a principal means of diagnosis; in addition, a pathogenic mutation in TSC1 or TSC2 is can be an independent diagnostic criterion. So in the current visit, gene analysis was performed for the patient and his parents. We detected a mutation of TSC2 gene in the propositus as follows: c.1513C>T; p.Arg505Ter; Het. However, no mutations were detected in his parents.
After discussing the benefits and potential complications of retinal photocoagulation and intravitreal anti-VEGF therapy, written informed consent was obtained from the patient. In the right eye, 577 nm yellow laser with a 200-mm spot diameter and 0.2 seconds duration was applied according to the fundus photography and FFA. RAHs that showed obvious fluorescence leakage were surrounded by laser spots. For RAHs close to the macula, SMLP was adopted to effectively control the RAH progression as well as protect the macula from photodamage. The laser power was determined by the visible laser scar of a trial photocoagulation created with continuous-wave mode for 0.2 seconds with a diameter of 100 mm outside the vascular arcade. In the left eye, intravitreal injection of 0.5 mg ranibizumab was administered to reduce leakage and exudation caused by the RAH inferior to the macula, which was advantageous for further photocoagulation treatment.
Six months after treatment, his VA improved to 20/25 OD. However, the BCVA OS decreased slightly from 20/40 to 20/50. Fundus photography OD showed that the RAHs were surrounded by photocoagulation spots. The number of RAHs remained stable, and there were no subretinal exudation, hemorrhage, and macular edema in the right eye (Fig. 4A, C) . However, the paramacular RAH in the left eye slightly enlarged (Fig. 4B) . OCT showed an increased macular thickness, enlarged intralesional optically empty space and posterior shadowing (Fig. 4D) . FFA revealed obvious fluorescein leakage from the paramacular RAH (Fig. 4E, F) . Therefore, photocoagulation was performed OS. The lesion inferior to the macula was treated by SMLP, and all the lesions that showed leakage in FFA were surrounded by 577 nm laser spots (Fig. 4G) . One month later, the VA was stable in the right eye and the BCVA of the left eye increased to 20/32. The patient was followed up in the following 3 months with no recurrence of exudation and the final BCVA was 20/25 OD and 20/32 OS.
Discussion
The TSC is an autosomal dominant disorder that results from pathogenic mutation in TSC1 or TSC2 tumor suppress gene. [4, 5] According to the latest diagnostic criteria, pathogenic mutation in TSC1 or TSC2 is an independent diagnostic criterion of TSC. [3] Previous studies indicate that TSC2 mutations generally produce a more severe phenotype than TSC1 mutations, and TSC2 mutations correlate with a higher rate of ophthalmologic findings than TSC1 mutations. [6, 18] The RAH is present in 30% to 50% of patients with TSC and is one of the major diagnostic criteria of TSC. [3] Typically, RAH is detected with fundoscopy, and the fundus manifestation is the most important diagnosis basis. OCT and FFA are useful in the detection of early stage RAH, and can help identify RAH from other retinal diseases such as retinoblastoma, sarcoidosis, tuberculous choroiditis, optic disc drusen, etc. The typical Yan et al. Medicine (2018) 97:50 Medicine characteristics of RAH in fundus photography are bilateral multiple grayish yellow nodules with or without calcification. [6] OCT characteristic features of the RAHs are abnormal thickening of the retinal nerve fiber layer, moth-eaten optically empty spaces, areas of dot-like high and low reflectivity, subretinal exudation, disorganization of the inner layer retina, retinal pigment epithelium layer, etc. [8, 19, 20] Previous studies found that type I RAH was the predominant type in children and type III was the predominant type in adult. [8, 19] In this case, both calcified and noncalcified RAHs are present with type I predominate OD and type III OS. Progression of RAH from none calcified type I to calcified types II and III with age, may explain the fundus feature of this patient.
Most of the RAHs are within retinal nerve fiber layer and do not cause vision problems for a long time. However, in a few cases, RAHs may progress and cause macular edema, exudative retinal detachment, neovascularization, and vitreous hemorrhage. [10, 14] For most patients, systemic lesions (including RAHs) are stable under adequate mTOR inhibitor treatment. However, in this case, systemic mTOR inhibitor was adopted with adequate dosage and duration, and the serum sirolimus concentration was maintained between 5 and 10 ng/mL, the RAHs still progress gradually. Therefore, active interventions for the RAHs were necessary to prevent further damage. The BCVA OD was stable after photocoagulation treatment, while the BCVA OS decreased slightly after intravitreal anti-VEGF injection. Given the prominent exudation caused by the paramacular RAH in the left eye, we decided to try to arrest leakage with micropulse photocoagulation.
Conventional lasers, such as krypton red, argon green and argon yellow laser have been used in the treatment of RAHs. [11, 21] Nevertheless, conventional laser photocoagulation occasionally causes undesirable adverse effect. The most common side effect is the thermal destruction of neurosensory retina which leads to subsequent vision impairment. Besides, conventional photocoagulation in the macular zone can induce choroidal neovascularization. The SMLP is a novel treatment for macular disorders such as diabetic macular edema and central serous chorioretinopathy. [22] The diffusion of heat to surrounding tissues is minimized in SMLP, thus scarring is prevented. In this case, we use 577 nm yellow laser for SMLP because xanthophyll (the pigment located in the inner and outer plexiform layers of the macula) absorbs the yellow light only minimally. So yellow light is relatively safe when applied near the fovea. To the best of our knowledge, this is the first report of TSCassociated RAHs that were successfully treated with 577 nm SMLP. Considering the different types and severity of RAHs, it is unknown whether SLMP therapy is effective in other cases. Therefore, studies with more patients and longer follow-up period are needed. 
Conclusion
The RAH occurs in nearly half of the patients with TSC. The finding of multiple RAHs is determined to be significant and specific enough as a major feature in the diagnosis of TSC. Although most RAHs in patients with TSC are stable throughout lifetime, in some rare cases, aggressive RAHs can lead to extensive exudation, neovascularization, and retinal detachment. RAHs that show obvious leakage in FFA and significant uplift in OCT should be treated timely and properly. Photocoagulation is an effective treatment for aggressive RAHs. About 577 nm subthreshold micropulse laser photocoagulation could be a novel treatment alternative for RAHs close to the macula.
